ライフサイエンスコーパス: withdrawal

1 se disorder treatment with medically managed withdrawal).

2 r (e.g., reservoir operation, and irrigation withdrawals).

3 cated, but it might increase the cost of OPV withdrawal.

4 intraabdominal conditions, and alcohol abuse/withdrawal.

5 due to chronic effects, ongoing use, or drug withdrawal.

6 p delayed graft function, or undergo steroid withdrawal.

7 garding seizure recurrences during and after withdrawal.

8 and reward, it does not lead to tolerance or withdrawal.

9 ariation influences the severity of nicotine withdrawal.

10 nacceptable toxicity, or other criterion for withdrawal.

11 predict recurrent DVT after anticoagulation withdrawal.

12 , and epileptiform abnormality on EEG before withdrawal.

13 ly increased at 8 and 24 h post-progesterone-withdrawal.

14 may influence providers' timing of treatment withdrawal.

15 se events leading to investigational product withdrawal.

16 ical inhibition of ATP breakdown exacerbates withdrawal.

17 orrelates with ethanol drinking during acute withdrawal.

18 ative mechanisms for functional progesterone withdrawal.

19 1) channel as a therapeutic target in opiate withdrawal.

20 proceeded did so within 30 min from time of withdrawal.

21 ion and ameliorated the sequelae of morphine withdrawal.

22 acted: please see Elsevier Policy on Article Withdrawal.

23 hile enhancing morphine-induced precipitated withdrawal.

24 inephrine signaling during drug exposure and withdrawal.

25 cohol seeking during the motivation test and withdrawal.

26 f thin spines that emerges after 1 month of withdrawal.

27 20 monotherapy until disease progression or withdrawal.

28 ent stresses caused by amino acid or glucose withdrawal.

29 not anandamide, was observed during nicotine withdrawal.

30 ess could be adapted to future stages of OPV withdrawal.

31 allergics' fell to 0% at 4 and 5 years after withdrawal.

32 ity can recur within days following allergen withdrawal.

33 ed with saline, nicotine, or undergoing 24 h withdrawal.

34 cognitive performance during early nicotine withdrawal.

35 reatment-emergent adverse events that led to withdrawal.

36 ting from chronic effects, continued use, or withdrawal.

37 n the off-label treatment of CUD or cannabis withdrawal.

38 rains, with symptomatic improvement on their withdrawal.

39 rmality on electroencephalogram (EEG) before withdrawal.

40 rotects tumor cells from serum growth factor withdrawal.

41 urveillance factor binding following glucose withdrawal.

42 d Dealing with Emotions Related to Treatment Withdrawal.

43 cumented patient harm and postmarket product withdrawals.

44 V crosslinking immediately following glucose withdrawal (0, 4, and 8 min).

45 ost common reasons for disqualification were withdrawal (8 persons [31%]), and not being medication r

46 on 4,995 participants were analysed after 11 withdrawals; 998 were assigned to, and 995 analysed (99.

47 On five separate days, craving, withdrawal, affect, and sustained attention were measure

48 The effects of EVR with early CNI withdrawal after HTx on albuminuria and renal function s

49 zure-free interval before antiepileptic drug withdrawal, age at onset of epilepsy, history of febrile

50 amatic symptoms that resolved after estrogen withdrawal alone.

51 n both males and females, spontaneous opioid withdrawal altered glucose metabolism in regions associa

52 autologous stem cell transplant before cART withdrawal alters viral dynamics: we found a higher rebo

53 behavior and brain activation during smoking withdrawal among smokers with ADHD.

54 chronic cocaine administration and following withdrawal, an acute cocaine challenge induced WAVE1 act

55 ollowed for a total of 5 years (1 year of IS withdrawal and 4 years off IS) with serial liver tests a

56 ndary outcomes included abstinence symptoms (withdrawal and craving) and cognitive test responding (N

57 B and NUMBL promote cardiomyocyte cell cycle withdrawal and highlight previously unsuspected connecti

58 pregnant mice also had delayed progesterone withdrawal and impaired myometrial function.

59 ow that paradigm shift in Indian groundwater withdrawal and management policies for sustainable water

60 ntinuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole.

61 , the underlying metabolic effects of opioid withdrawal and replacement have not been examined.

62 loped naloxone-precipitated somatic signs of withdrawal and spontaneous withdrawal-induced mechanical

63 aloxone-precipitated somatic signs of opioid withdrawal and spontaneous withdrawal-induced mechanical

64 lism in males and females following morphine withdrawal and subsequent methadone or buprenorphine rep

65 s ATP release from microglia during morphine withdrawal and that degrading endogenous spinal ATP by a

66 gness to receive palliative care or terminal withdrawal and the factors influencing willingness.

67 ) increase in the NAc core after 1 month of withdrawal and thereafter mediate the expression of incu

68 the adaptive immune response following cART withdrawal and viral rebound.

69 Trial withdrawals and adverse events of rash, dizziness, and d

70 sent two scenarios of changes in human water withdrawals and return flow to the system (individually

71 All cigarettes equally alleviated craving, withdrawal, and negative affect in the whole sample, but

72 ed in mesenchymal cells in response to serum withdrawal, and overexpression of VM-inhibiting miRNAs a

73 and maintenance of nicotine taking, nicotine withdrawal, and persistent nicotine seeking even after p

74 shes; cannabis use disorders (CUD), cannabis withdrawal, and psychiatric comorbidity.

75 tion-related phenomena, such as drug intake, withdrawal, and relapse.

76 ermined by M30 levels, occurs during alcohol withdrawal, and survival data point toward a novel under

77 lastic changes in EtOH-induced anxiolysis or withdrawal anxiety, and the presence or absence of EtOH-

78 ed by setting a reasonably firm date for OPV withdrawal as far in advance as possible, ideally at lea

79 withdrawal syndrome, and Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) sco

80 syndrome was defined as having at least two Withdrawal Assessment Tool-Version 1 scores greater than

81 ably, these changes persisted even after PQQ withdrawal at weaning.

82 information on agricultural water needs and withdrawals at appropriate spatial and temporal scales r

83 Corticosteroid withdrawal/avoidance in pediatric renal transplantation

84 was to examine the effect of corticosteroid withdrawal/avoidance on growth and safety parameters in

85 servational studies comparing corticosteroid withdrawal/avoidance to controls receiving corticosteroi

86 enal RCTs (n = 5) showed that corticosteroid withdrawal/avoidance was associated with a significant i

87 Corticosteroid withdrawal/avoidance was not associated with acute rejec

88 Using a trophic factor withdrawal-based model of neurodegeneration in both male

89 -point CGI-S score increases from randomized withdrawal baseline), was analyzed using a log-rank test

90 reatly improves cell viability after glucose withdrawal, because conservation of glutamate enables ce

91 eavy drinkers primarily admitted for alcohol withdrawal before and after alcohol detoxification.

92 dministering apyrase produces a reduction in withdrawal behaviors.

93 prefrontal cortex during an early period of withdrawal, but instead modifies a Hebbian quantitative

94 ssion, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response.

95 ct size, 0.753; P < .001) and suppression of withdrawal (Clinical Opiate Withdrawal Scale, CAM2038, 2

96 elf-administered cocaine prior to the 14-day withdrawal compared with levels in saline controls.

97 e both practical and rigorous such that tOPV withdrawal could be reasonably employed and confirmed in

98 nalysis results also show that reduced human withdrawals could help with regime change in some aquife

99 in the present study, we killed rats at four withdrawal day (WD) time-points (WD14, WD25, WD36, or WD

100 A composite of (1) withdrawals due to safety concerns, (2) FDA issuance of

101 that nicotine exposure, independent of drug withdrawal effects, increases stress sensitivity, a majo

102 arijuana could exert rewarding and addictive/withdrawal effects.

103 nt may begin working after a single exposure/withdrawal episode.

104 drawal, number of antiepileptic drugs before withdrawal, female sex, family history of epilepsy, numb

105 litate prediction of outcomes following drug withdrawal for the individual patient, including both th

106 1.17 [SE, .09]; P = .006), suggesting higher withdrawal for those groups during those periods.

107 This depletion is primarily due to water withdrawals for irrigation, but its connection with the

108 Following withdrawal from all interfering medications, patients we

109 njury (DILI) remains a leading cause of drug withdrawal from human clinical trials or the marketplace

110 we advanced a new hypothesis for the Mongol withdrawal from Hungary in 1242 CE, based on a joint ana

111 We show that withdrawal from morphine induces long-term synaptic faci

112 Withdrawal from nicotine is an important contributor to

113 care professionals, leading to frustration, withdrawal from patient care, and job abandonment.

114 In response to early withdrawal from repeated cocaine administration, de novo

115 Early withdrawal from repeated cocaine also produces dramatic

116 in's reward circuitry are observed following withdrawal from several abused drugs, including cocaine.

117 r DRN produced anxiety-like behavior, as did withdrawal from ShA or LgA cocaine self-administration.

118 o permanent discontinuation of study drug or withdrawal from study were similar between the treatment

119 ssion, death, unacceptable toxic effects, or withdrawal from study.

120 We report here that in rats at 24 h withdrawal from systemic ethanol administration (either

121 study group every 4 days and at the time of withdrawal from the study, due to cessation of sedation,

122 No serious adverse events led to withdrawal from the study.

123 cocaine craving has been demonstrated after withdrawal from this regimen; furthermore, Ca(2+)-permea

124 e risk-adjusted rate of in-hospital death or withdrawal from treatment was not significantly differen

125 There were no serious adverse events and no withdrawals from the study.

126 There were more withdrawals from the trial in the cannabidiol group.

127 Supervised withdrawal (ie, detoxification) from opioids using cloni

128 me-wide association study of DSM-IV nicotine withdrawal in a sample of African American (AA) and Euro

129 cterized by symptom improvement after gluten withdrawal in absence of celiac disease.

130 ssociated with EVR treatment after early CNI withdrawal in de novo HTx is unknown.

131 ular difference in the control of cell cycle withdrawal in fetal and postnatal myogenic stem cells, a

132 d full donor chimerism and immunosuppression withdrawal in highly mismatched allograft recipients usi

133 Repeated cycles of alcohol consumption and withdrawal in mice strengthened glutamatergic transmissi

134 The CB1 antagonist rimonabant precipitated withdrawal in mice treated chronically with WIN55,212-2

135 horigenic opioid effects and suppress opioid withdrawal in non-treatment-seeking individuals with OUD

136 vity at rest, as well as strong PNS activity withdrawal in response to the mental effort.

137 ease from microglia is required for morphine withdrawal in rodents and that blocking Panx1 alleviates

138 ability (n=4 [4%]) were the main reasons for withdrawal in the cabotegravir group.

139 ntibody, delayed graft function, and steroid withdrawal; in these groups, cytolytic induction substan

140 l depletion of activated T cells by cytokine withdrawal induced death (CWID) and TCR restimulation in

141 ocampus resulted in amelioration of nicotine withdrawal-induced anxiety-like behavior in the Novelty-

142 somatic signs of withdrawal and spontaneous withdrawal-induced mechanical hypersensitivity.

143 c signs of opioid withdrawal and spontaneous withdrawal-induced mechanical hypersensitivity.

144 e of neuropeptides in the brain after a long withdrawal interval when animals show incubation of meth

145 Tobacco withdrawal is associated with deficits in cognitive func

146 Withdrawal is therefore a key determinant of opiate use

147 y of oxycodone or the expression of physical withdrawal, it opposes the development of oxycodone tole

148 e Immune Tolerance Network immunosuppression withdrawal (ITN030ST) and Clinical Trials in Organ Trans

149 r myocytes to undergo appropriate cell cycle withdrawal leads to ventricular noncompaction and heart

150 ent-rated Aberrant Behavior Checklist Social Withdrawal/Lethargy subscale.

151 ontrol animals undergoing spontaneous opioid withdrawal, male animals treated with methadone exhibite

152 alleviate or avoid the aversive symptoms of withdrawal, many of these individuals continue to use op

153 and -gamma genes and their role in nicotine withdrawal may inform the development of novel smoking c

154 l because cognitive deficits during nicotine withdrawal may predict relapse in humans.

155 We conducted a phase 3, randomized withdrawal, multicenter, placebo-controlled, double-blin

156 Smoking withdrawal negatively impacts inhibitory control, and th

157 zure-free interval before antiepileptic drug withdrawal, number of antiepileptic drugs before withdra

158 ncer, intolerable adverse events, or consent withdrawal occurred.

159 ts completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide

160 Plan exit, defined as the withdrawal of a managed care plan from a state's Medicai

161 to lead to prolonged viral suppression after withdrawal of all therapeutic interventions.

162 ecular responses in C2C12 murine myotubes to withdrawal of ammonium acetate following 24-hour exposur

163 ially reversed following 24-hour and 48-hour withdrawal of ammonium acetate.

164 Cardiac MR imaging guided the initiation and withdrawal of anticoagulants.

165 The intervention comprised withdrawal of antidiabetic and antihypertensive drugs, t

166 ilepsy who were seizure-free and had started withdrawal of antiepileptic drugs; articles also had to

167 health efforts, such as the eventual global withdrawal of bOPV.

168 timal growth of melanoma cells following the withdrawal of BRAF inhibition.

169 rrent knowledge in the field focusing on the withdrawal of cardiac myocytes from the cell cycle durin

170 From April 2017, China will implement the withdrawal of colistin as a growth promoter, removing ov

171 r disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.

172 Treatment continued until progression, withdrawal of consent, or medical necessity.

173 y until disease progression, intolerability, withdrawal of consent, or study termination.

174 ase progression, unacceptable toxicities, or withdrawal of consent.

175 occurrence of unacceptable toxic effects, or withdrawal of consent.

176 l appendicectomy group were withdrawn due to withdrawal of consent; two in the active observation gro

177 of the defense mechanisms of the host is the withdrawal of essential metal ions, in particular iron,

178 ave observed a reduction in growth rate upon withdrawal of folate.

179 -dependent mechanism of rescue following the withdrawal of genotoxic agent.

180 Withdrawal of glucose or glutamine induced G1 and G2/M a

181 st is important to decide on continuation or withdrawal of intensive care.

182 e patient quietly seated following overnight withdrawal of levodopa and after administration of levod

183 ecause referral occurred after initiation of withdrawal of life-sustaining therapy or not at all.

184 Of 1,407 patient deaths following planned withdrawal of life-sustaining therapy, 54.0% (n = 760) w

185 ients and families throughout the process of withdrawal of life-sustaining treatment.

186 Withdrawal of life-sustaining treatments.

187 ted at determining what factors predict when withdrawal of medications in those who are seizure free

188 Interestingly, we observed a rapid physical withdrawal of mural cells from the endothelium that was

189 may explain these associations, such as the withdrawal of older adults from situations in which they

190 eeded for a thorough, synchronized, and full withdrawal of OPV, and such preparation would be aided b

191 trategic Plan 2013-2018 calls for the phased withdrawal of OPV, beginning with the globally synchroni

192 V (bOPV) can inform the eventual full global withdrawal of OPV.

193 The phased withdrawal of oral polio vaccine (OPV) associated with t

194 f polio eradication which calls for a phased withdrawal of oral polio vaccine beginning with the type

195 Global Polio Eradication Initiative to begin withdrawal of oral polio vaccines (OPV), beginning with

196 Unexpectedly, following withdrawal of teriparatide therapy, bone marrow adipocyt

197 debate on the mechanisms involved including withdrawal of the carcinogenic effects of calcineurin in

198 program coincident with, or even preceding, withdrawal of the stimulated paw.

199 nd the remaining one experienced a transient withdrawal of tinnitus.

200 ArcN), and this action requires simultaneous withdrawal of tonic neuropeptide Y (NPY) sympathoinhibit

201 least 2 years remain disease-free after the withdrawal of treatment.

202 The withdrawal of trivalent OPV provided a number of useful

203 x-year follow-up study on the effects of PHO withdrawal on IgE sensitization and anaphylaxis reportin

204 on of each population mediates either social withdrawal or behavioral despair, but not both.

205 els were doubled in vitro by either nutrient withdrawal or gemcitabine treatment, but depriving PDAC

206 ement was observed in parallel with complete withdrawal or reduction of other immunotherapies, with a

207 ound no significant improvements in craving, withdrawal, or cognitive function.

208 ession, unacceptable adverse events, consent withdrawal, or death.

209 omosome 5 that were associated with nicotine withdrawal (P<5 x 10(-8)).

210 ling with small-molecule inhibitors or IGF-1 withdrawal partially abrogates both the phosphorylation

211 253 enrolled in the double-blind randomized withdrawal period (127 in the placebo group; 126 in the

212 The method could be applied to monitoring withdrawal period specified for ivermectin in cattle.

213 statement tests following an extended 3 week withdrawal period.

214 period and a 26-week double-blind randomized withdrawal period.

215 multicentre, placebo-controlled, randomised withdrawal phase 2a trial in 25 secondary care centres i

216 e during a 26-week, double-blind, randomized withdrawal phase.

217 mpus separately in mediating select nicotine withdrawal phenotypes.

218 tic plasticity may underlie certain nicotine withdrawal phenotypes.

219 nd spine density changes induced by nicotine withdrawal precipitated by the nicotinic antagonist meca

220 ronic pain and are associated with low trial withdrawal rate and better patient satisfaction.

221 rse events, incidence of constipation, trial withdrawal rate, and patient satisfaction with treatment

222 providing better tolerability and less trial withdrawal rate.

223 e that smoking-induced relief of craving and withdrawal reflects primarily non-nicotine effects in sl

224 g menstrual phase and 24 h post-progesterone-withdrawal respectively.

225 al and thermal hyperalgesia as tested by the withdrawal responses of the ipsilateral footpad to von F

226 Glucose or glutamine withdrawal resulted in a 5- to 10-fold protective effect

227 e glutamate receptors (CP-AMPARs) after drug withdrawal results in profound remodeling of NAc neuro-c

228 Time-course analyses of withdrawal revealed significant effects of phase (taper,

229 letion of biotinylated proteins after biotin withdrawal revealed that Pyc is the most rapidly deplete

230 icotine infusion, abstinent smokers with the withdrawal risk allele experienced greater alleviation o

231 (taper, post taper) for the Clinical Opiate Withdrawal Scale (COWS) score (taper mean, 5.19 [SE, .26

232 F2,170 = 3.6, P = .03) and Subjective Opiate Withdrawal Scale (SOWS) score (taper mean,8.81 [SE, .40]

233 All doses reduced Minnesota Nicotine Withdrawal Scale total scores (range of mean decreases,

234 d suppression of withdrawal (Clinical Opiate Withdrawal Scale, CAM2038, 24 mg: effect size, 0.617; P

235 tive effects, such as the Minnesota Nicotine Withdrawal Scale.

236 g scale (eg, high and desire to use), opioid withdrawal scales, and physiological and pharmacokinetic

237 otential, is effective for use in supervised withdrawal settings.

238 obenecid, suppressed ATP release and reduced withdrawal severity.

239 understood, and strategies for complete drug withdrawal should be selected carefully to avoid graft r

240 nteroceptive processing in the mid-insula of withdrawal signals from the body potentiates the motivat

241 1) and second (P2), three-year periods after withdrawal, significant falls in total reports (P < 0.00

242 double-blind, placebo-controlled, randomized withdrawal study including 418 participants was conducte

243 randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to

244 immediate and sustained opioid blockade and withdrawal suppression.

245 and function, playing a crucial role in EtOH withdrawal symptoms and dependence.

246 ation and nicotine on suppression of tobacco withdrawal symptoms and smoking behavior.

247 mparable to buprenorphine in reducing opioid withdrawal symptoms during a residential tapering progra

248 Some withdrawal symptoms or relapses may have been missed.

249 .05; P < .001 for all), although duration of withdrawal symptoms was greater at higher doses (eta2 =

250 ate drug (that is, without relapse or severe withdrawal symptoms) and clinical outcomes (neuropsychia

251 d repeated self-report measures (ie, tobacco withdrawal symptoms, smoking urge, and negative affect (

252 severity, function, quality of life, opioid withdrawal symptoms, substance use, and adverse events.

253 of tramadol ER as a method to manage opioid withdrawal symptoms.

254 ne was released in the vBNST during specific withdrawal symptoms.

255 id-mediated effects, including analgesia and withdrawal symptoms.

256 before weaning to better prevent iatrogenic withdrawal syndrome among at-risk patients.

257 rrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens in patients wit

258 Measures included occurrence of alcohol withdrawal syndrome and delirium tremens, injury charact

259 gth of stay, ICU length of stay, and alcohol withdrawal syndrome complications differed significantly

260 Alcohol withdrawal syndrome developed in 0.88% (n = 246), includ

261 Trauma patients with alcohol withdrawal syndrome experience a high occurrence of deli

262 n of opiate therapy can cause a debilitating withdrawal syndrome in chronic users.

263 dictive model of risk factors for iatrogenic withdrawal syndrome in critically ill children.

264 alyses, significant predictors of iatrogenic withdrawal syndrome included younger age, preexisting co

265 Iatrogenic withdrawal syndrome is common in children recovering fro

266 Alcohol withdrawal syndrome progressed to delirium tremens in 11

267 eline CIWA-Ar score, and established alcohol withdrawal syndrome risk factors.

268 plications differed significantly by alcohol withdrawal syndrome severity and were worse with more se

269 Before adjustment, alcohol withdrawal syndrome severity was associated with injury

270 Alcohol withdrawal syndrome severity was defined by CIWA-Ar scor

271 Iatrogenic withdrawal syndrome was defined as having at least two W

272 utcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical Institute Withdrawal A

273 ry characteristics, risk factors for alcohol withdrawal syndrome, clinical outcomes, pharmacologic tr

274 rrupting PD treatment might lead to a severe withdrawal syndrome.

275 e with more severe manifestations of alcohol withdrawal syndrome.

276 ealthcare system risk factors for iatrogenic withdrawal syndrome.

277 osure, and increased frequency of iatrogenic withdrawal syndrome.

278 enced more clinically significant iatrogenic withdrawal than moderate/severe pediatric acute respirat

279 s reported greater reductions of craving and withdrawal than slow metabolizers, with dose-dependent e

280 d effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and resu

281 Following cART withdrawal, the memory component of the virus-specific a

282 Six years after PHO withdrawal, the Norwegian population has become signific

283 Finally, mechanical withdrawal threshold revealed a full preventive action a

284 tor agonist increased thermal and mechanical withdrawal thresholds during zymosan-induced inflammatio

285 red using either thyroid-stimulating hormone withdrawal (THW) or recombinant human thyroid-stimulatin

286 for FUSE vs 19.1 min for FVC; P = .32), but withdrawal time was significantly longer for FUSE (15.8

287 On WD36, approximately the withdrawal time when stable elevation of CP-AMPAR levels

288 Correcting for per-unit withdrawal time, the mean dysplasia miss rate per subjec

289 ection combined with arterial catheter blood withdrawal to achieve a sustained systolic blood pressur

290 involving ground-state electron donation or withdrawal to/from the MoS2 nanosheets, which modifies t

291 Memory impairment during nicotine withdrawal was blocked by the CB1R antagonist rimonabant

292 caine following chronic cocaine exposure and withdrawal, we also observed in WT, but not in WAVE1 D1-

293 R diagnostic miRNAs during immunosuppression withdrawal were also evaluated in sera taken at predeter

294 jections showed that alcohol consumption and withdrawal were associated with generation of silent syn

295 s operationally tolerant through complete IS withdrawal, were followed for a total of 5 years (1 year

296 d 4 days after the precipitation of nicotine withdrawal, when the cognitive deficits were still prese

297 tabolic shift in wild type cells upon biotin withdrawal which was blunted in cell lacking Pyc.

298 ersely, dopamine output was decreased during withdrawal, while norepinephrine was released in the vBN

299 in HuR in preserving survival under nutrient withdrawal, with or without gemcitabine.

300 at blocking Panx1 alleviates the severity of withdrawal without affecting opiate analgesia.